Efficacy of galactose and adalimumab in patients with resistant focal segmental glomerulosclerosis: report of the font clinical trial group

BACKGROUND: Patients with resistant focal segmental glomerulosclerosis (FSGS) who are unresponsive to corticosteroids and other immunosuppressive agents are at very high risk of progression to end stage kidney disease. In the absence of curative treatment, current therapy centers on renoprotective i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Nephrol
Autores principales: Trachtman, Howard, Vento, Suzanne, Herreshoff, Emily, Radeva, Milena, Gassman, Jennifer, Stein, Daniel T., Savin, Virginia J., Sharma, Mukut, Reiser, Jochen, Wei, Changli, Somers, Michael, Srivastava, Tarak, Gipson, Debbie S.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4511259/
https://ncbi.nlm.nih.gov/pubmed/26198842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12882-015-0094-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares